Global Blood Therapeutics logo
Global Blood Therapeutics GBT
report update icon

Quarterly report 2022-Q2
added 05-30-2026

Global Blood Therapeutics Net Income | GBT

Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.

Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]

It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.

The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.

Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.

It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.

However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.

Annual Net Income Global Blood Therapeutics

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
-303 M -248 M -267 M -174 M -117 M -82.5 M -46.4 M -20.8 M -18.1 M - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
-18.1 M -303 M -142 M

Quarterly Net Income Global Blood Therapeutics

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
- - -82.5 M -81.4 M - -71 M -69.6 M -74.9 M -61.8 M -59.9 M -52.8 M -73 M -96 M -64.5 M -57.3 M -48.9 M -49.2 M -43.1 M -40.4 M -41.6 M -41.3 M -28.6 M -23.9 M -23.3 M -27.2 M -21 M -17.7 M -16.6 M -15.6 M -14.8 M -8.59 M -7.42 M -5.31 M -5.22 M -5.16 M -5.11 M - - - - - - - - - - - -

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
-5.11 M -96 M -40.4 M

References

  1. Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.

Net Income of other stocks in the Biotechnology industry

Issuer Net Income Price % 24h Market Cap Country
Innoviva Innoviva
INVA
271 M $ 18.36 0.3 % $ 1.24 B usaUSA
BioCardia BioCardia
BCDA
-8.23 M $ 0.77 -2.06 % $ 5.13 M usaUSA
Kindred Biosciences, Inc. Kindred Biosciences, Inc.
KIN
-21.8 M - 0.11 % $ 419 M usaUSA
Syndax Pharmaceuticals Syndax Pharmaceuticals
SNDX
-285 M $ 8.55 -7.07 % $ 741 M usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
-12.1 M $ 1.72 -7.77 % $ 11 B australiaAustralia
Shineco, Inc. Shineco, Inc.
TYHT
-6.63 M - -3.90 % $ 97.2 M chinaChina
ORIC Pharmaceuticals ORIC Pharmaceuticals
ORIC
-129 M $ 7.66 -4.25 % $ 673 M usaUSA
Oramed Pharmaceuticals Oramed Pharmaceuticals
ORMP
75.3 K $ 3.9 0.78 % $ 161 M israelIsrael
Certara Certara
CERT
-1.6 M $ 11.25 1.72 % $ 1.8 B usaUSA
PainReform Ltd. PainReform Ltd.
PRFX
-5.02 M $ 0.63 -4.8 % $ 408 K israelIsrael
Intec Pharma Ltd Intec Pharma Ltd
NTEC
-14.1 M - -12.45 % $ 17.7 M israelIsrael
Anika Therapeutics Anika Therapeutics
ANIK
-11 M $ 13.74 6.89 % $ 197 M usaUSA
Prothena Corporation plc Prothena Corporation plc
PRTA
-244 M $ 8.38 1.39 % $ 451 M usaUSA
Aprea Therapeutics Aprea Therapeutics
APRE
-12.6 M $ 0.46 2.6 % $ 3.01 M usaUSA
Galectin Therapeutics Galectin Therapeutics
GALT
-30.8 M $ 3.0 2.92 % $ 192 M usaUSA
Processa Pharmaceuticals Processa Pharmaceuticals
PCSA
-13.6 M $ 1.7 -2.3 % $ 2.23 M usaUSA
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
CORT
99.7 M $ 67.94 -3.04 % $ 7.06 B usaUSA
Progenity, Inc. Progenity, Inc.
PROG
-193 M - -3.47 % $ 164 M usaUSA
China SXT Pharmaceuticals China SXT Pharmaceuticals
SXTC
-6.21 M $ 2.84 -0.7 % $ 1.93 M chinaChina
Genprex Genprex
GNPX
-16.2 M $ 1.73 3.56 % $ 1.61 M usaUSA
Strongbridge Biopharma plc Strongbridge Biopharma plc
SBBP
-45.1 M - 1.52 % $ 136 M usaUSA
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
TAK
108 B $ 21.27 -1.71 % $ 33.6 B japanJapan
Protara Therapeutics Protara Therapeutics
TARA
-57.4 M $ 2.33 0.22 % $ 99.8 M usaUSA
Innate Pharma S.A. Innate Pharma S.A.
IPHA
-49.2 M $ 1.0 -24.81 % $ 89.6 M franceFrance
Seneca Biopharma, Inc. Seneca Biopharma, Inc.
SNCA
-16.3 M - -1.19 % $ 28.7 M usaUSA
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
349 M $ 61.57 5.22 % $ 11.8 B usaUSA
Bio-Techne Corporation Bio-Techne Corporation
TECH
182 M $ 72.74 0.15 % $ 11.3 B usaUSA
Matinas BioPharma Holdings Matinas BioPharma Holdings
MTNB
-10.3 M $ 0.91 6.35 % $ 4.98 M usaUSA
Enanta Pharmaceuticals Enanta Pharmaceuticals
ENTA
-68.2 M $ 8.21 -5.52 % $ 175 K usaUSA
Milestone Pharmaceuticals Milestone Pharmaceuticals
MIST
-63.1 K $ 0.46 10.45 % $ 48.9 M canadaCanada
Teva Pharmaceutical Industries Limited Teva Pharmaceutical Industries Limited
TEVA
1.41 B $ 42.18 -1.04 % $ 48.3 B israelIsrael
Scholar Rock Holding Corporation Scholar Rock Holding Corporation
SRRK
-378 M $ 47.99 6.46 % $ 5.5 B usaUSA
Lipocine Lipocine
LPCN
-9.63 M $ 1.54 -3.75 % $ 8.39 M usaUSA
Seres Therapeutics Seres Therapeutics
MCRB
5.7 M $ 1.45 2.48 % $ 12.8 M usaUSA
Madrigal Pharmaceuticals Madrigal Pharmaceuticals
MDGL
-288 M $ 398.15 -5.65 % $ 8.93 B usaUSA
CEL-SCI Corporation CEL-SCI Corporation
CVM
-25.4 M $ 1.38 -25.41 % $ 11.1 M usaUSA
Inventiva S.A. Inventiva S.A.
IVA
-184 M $ 3.4 5.43 % $ 203 M franceFrance
MeiraGTx Holdings plc MeiraGTx Holdings plc
MGTX
-114 M $ 8.3 -1.89 % $ 668 M usaUSA
Trevi Therapeutics Trevi Therapeutics
TRVI
-42.8 M $ 13.55 0.26 % $ 1.83 B usaUSA
Eton Pharmaceuticals Eton Pharmaceuticals
ETON
-4.6 M $ 62.05 -2.51 % $ 1.67 B usaUSA
IDEAYA Biosciences IDEAYA Biosciences
IDYA
-114 M $ 26.13 -4.64 % $ 2.31 B usaUSA
Protalix BioTherapeutics Protalix BioTherapeutics
PLX
-6.6 M $ 2.96 1.9 % $ 232 M israelIsrael
Lantern Pharma Lantern Pharma
LTRN
-17.1 M $ 0.33 -10.93 % $ 3.6 M usaUSA
Foghorn Therapeutics Foghorn Therapeutics
FHTX
-74.3 M $ 1.8 -1.91 % $ 113 M usaUSA
Ocugen Ocugen
OCGN
-68 M $ 0.73 -2.88 % $ 228 M usaUSA
Oncolytics Biotech Oncolytics Biotech
ONCY
-31.7 M $ 0.44 15.71 % $ 42.2 M canadaCanada
Minerva Neurosciences Minerva Neurosciences
NERV
-293 M $ 2.18 0.93 % $ 18.5 M usaUSA
Kamada Ltd. Kamada Ltd.
KMDA
20.2 M $ 8.07 -1.04 % $ 465 M israelIsrael
Neurocrine Biosciences Neurocrine Biosciences
NBIX
479 M $ 162.75 -1.91 % $ 16.2 B usaUSA